Lenacapavir, a potent first-in-class inhibitor of HIV-1 capsid function, is in development for treatment and prevention of HIV-1 infection. Dr Onyema Ogbuagu (Yale School of Medicine, New Haven, CT, USA) discusses the ongoing phase 2/3 CAPELLA study, investigating lenacapavir in combination with an optimized background regimen treatment-experienced people with HIV-1, with multidrug-resistance and ongoing viremia.
The abstract entitled: ‘Long-Acting Lenacapavir in People with Multidrug Resistant HIV-1: Week 52 Results’ (Abstract #496) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What are the unmet needs of people living with HIV infection? (0:14)
- What is the mechanism of action of lenacapavir and what are its potential advantages over existing HIV therapies? (1:21)
- What were the aims, methodology and findings of the CAPELLA trial? (3:02)
- What will be the next steps in the clinical development of lenacapavir in this indication? (7:57)
Disclosures: Onyema Ogbuagu is on advisory boards for Gilead Sciences and ViiV Healthcare and a speaker’s Bureau participant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!